TLSI insider trading
HealthcareTriSalus Life Sciences, Inc.: insider trade history from SEC Form 4 filings.
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Company website: trisaluslifesci.com
TLSI insider activity at a glance
FilingIQ tracks 113 insider transactions for TLSI in filings since Aug 14, 2023. The most recent transaction is dated Oct 5, 2026.
Across the full history, 28 open-market purchases
and 25 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TLSI insider trades is 66.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TLSI Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading TLSI
Frequently asked
- How many insider trades does FilingIQ track for TLSI?
- FilingIQ tracks 113 Form 4 insider transactions for TLSI (TriSalus Life Sciences, Inc.), covering filings from Aug 14, 2023 onwards. 4 of those are dated within the last 90 days.
- Are TLSI insiders net buyers or net sellers?
- Across the full Form 4 history for TLSI, 28 transactions (25%) were open-market purchases and 25 (22%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TLSI insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is TLSI in?
- TriSalus Life Sciences, Inc. (TLSI) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $237.33M.
Methodology & sources
Every TLSI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.